Central serous chorioretinopathy
Conditions
Interventions
3mg/m2 intravenous infusion of verteporfin over 10 minutes followed by delivery of diode laser at 689nm 15 minutes after the start of the infusion. Light dose rate is 600 mW/cm2, time of photosensit
Sponsors
Nagoya University School of Medicine Department of Ophthalmology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. 3 months or more after onset 2. presence of active angiographic leakage under or adjacent to fovea in fluorescein angiography 3. presence of serous retinal detachment(SRD) on optical coherence tomography(OCT) 4. written informed consent 5. re-treatment is considered to the patients with recurrent or persistent SRD on OCT
Exclusion criteria
Exclusion criteria: 1. drug allery to verteporfin 2. pregnant or expecting pregnancy 3. porphyria, or hypersensitivity to artificial illumination 4. macular diseases other than CSC 5. others (inappropriate case judged by investigator or subinvestigators)
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| 1)visual acuity 2)optical coherence tomography 3)amplitudes and implicit time of a-wave, b-wave and odcillatory potentials recorded by focal macula electroretinogram 4)visual field 5)fluorescein angiography 6)indocyanine green angiography time of assessment 1)-5) : 4 days, 1 month, 3 months and 1 year after PDT 6),7) : 1 month, 3 months and 1 year after PDT | — |
Primary
| Measure | Time frame |
|---|---|
| resolution of serous retinal detachment of 4 days, 1 month, 3 months and 1 year after PDT | — |
Countries
Japan
Contacts
Public ContactRuka Maruko
Nagoya University School of Medicine Department of Ophthalmology
Outcome results
None listed